Acrivon Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Acrivon Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2021 to Q2 2024.
  • Acrivon Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $2.64M, a 64.3% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $1.49M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.64M +$1.03M +64.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $1.18M -$455K -27.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q3 2023 $5.93M $1.67M +$1.29M +343% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $4.64M $1.61M +$1.5M +1430% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $3.14M $1.64M +$1.65M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $1.49M $1.02M Oct 1, 2022 Dec 31, 2022 10-K 2023-03-28
Q3 2022 $377K +$146K +63.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $105K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$8K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 $231K Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.